278 related articles for article (PubMed ID: 19469207)
1. [Patient compliance program aids therapy success].
MMW Fortschr Med; 2009 Mar; 151(11):47. PubMed ID: 19469207
[No Abstract] [Full Text] [Related]
2. [Postmenopausal osteoporosis. Bisphosphonates are not all equal].
MMW Fortschr Med; 2009 Mar; 151(11):46-7. PubMed ID: 19469206
[No Abstract] [Full Text] [Related]
3. [Substance properties of zoledronate make it possible: bisphosphonate therapy only once yearly].
MMW Fortschr Med; 2006 Jun; 148(25):60-1. PubMed ID: 16859169
[No Abstract] [Full Text] [Related]
4. [Osteoporosis therapy. Bisphosphonates compared].
MMW Fortschr Med; 2003 Mar; 145(13):60. PubMed ID: 15101545
[No Abstract] [Full Text] [Related]
5. [Calcium gaps in osteoporosis patients close. Blister pack simplifies comedication of calcium and bisphosphonates].
MMW Fortschr Med; 2005 Apr; 147(14):44. PubMed ID: 15887685
[No Abstract] [Full Text] [Related]
6. [Excellent adjustment with greater action. To pay attention to improving compliance].
MMW Fortschr Med; 2005 Apr; 147(14):45. PubMed ID: 15887686
[No Abstract] [Full Text] [Related]
7. [Correlation between studies and general practice].
MMW Fortschr Med; 2006 Nov; 148(46):49. PubMed ID: 17615791
[No Abstract] [Full Text] [Related]
8. [To increase bone density faster and stronger].
MMW Fortschr Med; 2005 May; 147(18):44-5. PubMed ID: 15934589
[No Abstract] [Full Text] [Related]
9. [FACT study: benefits of alendronate].
MMW Fortschr Med; 2005 Jan; 147(1-2):52-3. PubMed ID: 15704574
[No Abstract] [Full Text] [Related]
10. Going on a drug holiday?
Bonnick SL
J Clin Densitom; 2011; 14(4):377-83. PubMed ID: 22051091
[No Abstract] [Full Text] [Related]
11. [Your patients face the treatment of osteoporosis: How to improve the efficacy of management in clinical practice?].
Thomas T; Reach G; Lespessailles E
Rev Prat; 2006 Jan; Spec No():3-11. PubMed ID: 16502833
[No Abstract] [Full Text] [Related]
12. [An advantage for compliance: alendronate once weekly].
MMW Fortschr Med; 2005 Dec; 147(49-50):75. PubMed ID: 16401017
[No Abstract] [Full Text] [Related]
13. [FACT study].
Tanaka I; Oshima H
Nihon Rinsho; 2007 Nov; 65 Suppl 9():280-5. PubMed ID: 18161120
[No Abstract] [Full Text] [Related]
14. [Osteoporosis compounds in general practice. That is REAL: in routine practice the better choice].
MMW Fortschr Med; 2007 Mar; 149(13):50. PubMed ID: 17672400
[No Abstract] [Full Text] [Related]
15. [What do we need to know--what can we do?].
Krankenpfl J; 2005; 43(7-10):217. PubMed ID: 16515289
[No Abstract] [Full Text] [Related]
16. [Efficacy and tolerability of once-weekly administration of 35 mg alendronate and 17.5 mg risedronate].
Kishimoto H
Nihon Rinsho; 2007 Nov; 65 Suppl 9():365-8. PubMed ID: 18161133
[No Abstract] [Full Text] [Related]
17. [Men also need bone protection].
MMW Fortschr Med; 2006 Nov; 148(46):48-9. PubMed ID: 17615790
[No Abstract] [Full Text] [Related]
18. European women's preference for osteoporosis treatment: influence of clinical effectiveness and dosing frequency.
Keen R; Jodar E; Iolascon G; Kruse HP; Varbanov A; Mann B; Gold DT
Curr Med Res Opin; 2006 Dec; 22(12):2375-81. PubMed ID: 17257451
[TBL] [Abstract][Full Text] [Related]
19. Corticosteroids: no drug prevention of fractures needed.
Prescrire Int; 2009 Aug; 18(102):175. PubMed ID: 19746563
[TBL] [Abstract][Full Text] [Related]
20. Long-term experience with alendronate in the treatment of osteoporosis.
Hochberg MC; Rizzoli R
Expert Opin Pharmacother; 2006 Jun; 7(9):1201-10. PubMed ID: 16732706
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
